Compare TTK HEALTHCARE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE CIPLA TTK HEALTHCARE/
CIPLA
 
P/E (TTM) x 10.6 32.0 33.1% View Chart
P/BV x 1.5 4.5 34.0% View Chart
Dividend Yield % 1.0 0.5 222.2%  

Financials

 TTK HEALTHCARE   CIPLA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-19
CIPLA
Mar-20
TTK HEALTHCARE/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,215586 207.5%   
Low Rs610357 171.0%   
Sales per share (Unadj.) Rs444.4207.0 214.6%  
Earnings per share (Unadj.) Rs17.218.6 92.7%  
Cash flow per share (Unadj.) Rs27.633.2 83.3%  
Dividends per share (Unadj.) Rs5.004.00 125.0%  
Dividend yield (eoy) %0.50.8 64.5%  
Book value per share (Unadj.) Rs177.9195.5 91.0%  
Shares outstanding (eoy) m14.13806.35 1.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.12.3 90.2%   
Avg P/E ratio x52.925.3 208.8%  
P/CF ratio (eoy) x33.014.2 232.5%  
Price / Book Value ratio x5.12.4 212.8%  
Dividend payout %29.021.5 134.8%   
Avg Mkt Cap Rs m12,894379,912 3.4%   
No. of employees `0002.325.8 8.9%   
Total wages/salary Rs m1,30730,270 4.3%   
Avg. sales/employee Rs Th2,715.76,459.6 42.0%   
Avg. wages/employee Rs Th565.31,171.2 48.3%   
Avg. net profit/employee Rs Th105.4580.2 18.2%   
INCOME DATA
Net Sales Rs m6,279166,949 3.8%  
Other income Rs m783,442 2.3%   
Total revenues Rs m6,356170,391 3.7%   
Gross profit Rs m49632,060 1.5%  
Depreciation Rs m14711,747 1.2%   
Interest Rs m341,974 1.7%   
Profit before tax Rs m39321,782 1.8%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1496,312 2.4%   
Profit after tax Rs m24414,995 1.6%  
Gross profit margin %7.919.2 41.1%  
Effective tax rate %37.929.0 130.9%   
Net profit margin %3.99.0 43.2%  
BALANCE SHEET DATA
Current assets Rs m2,717117,038 2.3%   
Current liabilities Rs m1,57143,931 3.6%   
Net working cap to sales %18.343.8 41.7%  
Current ratio x1.72.7 64.9%  
Inventory Days Days3296 33.6%  
Debtors Days Days4785 54.8%  
Net fixed assets Rs m991107,424 0.9%   
Share capital Rs m1411,613 8.8%   
"Free" reserves Rs m2,373156,018 1.5%   
Net worth Rs m2,514157,630 1.6%   
Long term debt Rs m323,693 0.0%   
Total assets Rs m4,158236,626 1.8%  
Interest coverage x12.612.0 104.8%   
Debt to equity ratio x00.2 0.9%  
Sales to assets ratio x1.50.7 214.0%   
Return on assets %6.77.2 93.1%  
Return on equity %9.79.5 101.9%  
Return on capital %16.912.8 131.9%  
Exports to sales %3.633.0 10.9%   
Imports to sales %0.50-   
Exports (fob) Rs m22555,175 0.4%   
Imports (cif) Rs m31NA-   
Fx inflow Rs m22556,036 0.4%   
Fx outflow Rs m716,764 1.1%   
Net fx Rs m15449,272 0.3%   
CASH FLOW
From Operations Rs m17330,685 0.6%  
From Investments Rs m971,040 9.3%  
From Financial Activity Rs m-307-29,488 1.0%  
Net Cashflow Rs m-382,340 -1.6%  

Share Holding

Indian Promoters % 65.4 16.0 408.8%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 3.7 12.2 30.3%  
FIIs % 5.2 23.7 21.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 25.8 26.2 98.5%  
Shareholders   12,723 161,166 7.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare TTK HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

India Top US Crude Oil Buyer in Q1CY21, Adani Ports Removed from S&P Index, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note on Tuesday. Benchmark indices extended gains after the Indian government fast-tracked emergency approvals for foreign produced Covid-19 vaccines.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 71.7% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Apr 13, 2021 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE 5-YR ANALYSIS

COMPARE TTK HEALTHCARE WITH

MARKET STATS